Navigation Links
Intradigm Closes Final Tranche of $21.4 Million Series B Financing
Date:1/7/2009

PALO ALTO, Calif., Jan. 7 /PRNewswire/ -- Intradigm Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, today announced that the company has closed the final tranche of its Series B financing. Astellas Venture Management led the $2.9 million tranche, with existing investor, Lilly Ventures, also participating. The addition of these funds brings the total Series B financing to $21.4 million. Intradigm will use Series B funds to advance its RNAi therapeutics platform, which is comprised of both its siRNA intellectual property, as well as its proprietary delivery technology, toward the development of systemic siRNA therapeutic candidates with an initial focus on cancer targets.

"Intradigm's uniquely comprehensive approach to developing RNAi therapeutics, which encompasses safe and effective delivery, proprietary siRNA sequences and novel structural features for RNAi molecules, makes the company an attractive investment in the rapidly growing RNAi space," said Shinja Yano, Ph.D., president and chief executive officer, Astellas Venture Management LLC. "We are excited to join Intradigm's group of investors and look forward to contributing to the company's future success in recognizing the substantial promise of RNAi as a therapeutic class."

Intradigm today also provided an update on recent corporate developments, announcing that Mohammad Azab, M.D., has resigned his position as chief executive officer but will retain his position on Intradigm's board of directors. Dr. Azab will be succeeded as chief executive officer by Philip Haworth, Ph.D., who previously served as the company's vice president of business development.

"The board would like to thank Dr. Azab for his valuable contributions to building the company and successfully raising the recent Series B financing. We are delighted that he will continue his strategic role on Intradigm's board," said J
'/>"/>

SOURCE Intradigm Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School
2. Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics
3. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
4. Genmab Discloses Target and Development Plans for HuMax-Inflam
5. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
6. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
7. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
8. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
9. BioVex Closes Second Round of Series E Financing
10. Pharmaxis Closes Share Purchase Plan
11. The closest look ever at native human tissue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Sept. 13 Genomatica announced today that ... company full time as executive chairman and chief business ... leading chemical producers, users, feedstock suppliers, brands and retailers. ... biotech leadership; $500 million in partnerships ...
... 10 PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ... all of the Company,s outstanding 2.75% Convertible Subordinated Notes, due ... Notes have been provided notice of the redemption by the ... holders who elect to convert their 2023 Notes into the ...
... Paratek Pharmaceuticals, Inc. today announced the Company,s lead ... the subject of several poster presentations at the ... (ICAAC).  Dr. Stuart Levy, co-founder and Chief Scientific ... talk at a symposium on antibiotic resistance at ...
Cached Biology Technology:Bill Baum Joins Genomatica as it Ramps for Commercial Rollout 2Bill Baum Joins Genomatica as it Ramps for Commercial Rollout 3Bill Baum Joins Genomatica as it Ramps for Commercial Rollout 4PDL BioPharma Provides Clarification Regarding Redemption of Its 2.75% Convertible Subordinated Notes 2Paratek to Present Clinical Data at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy 2Paratek to Present Clinical Data at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy 3
(Date:12/17/2014)... 16, 2014  Automation is fundamentally transforming the ... than at international borders. Over the past decade, ... allowed veteran travelers to self process through border ... Kiosks at an increasing number of airports, seaports, ... According to Maxine Most , Principal ...
(Date:12/11/2014)... 10, 2014  Data Sciences International (DSI), the ... a new series of digital telemetry implants to ... M series, part of the PhysioTel™ Digital platform, ... possible physiologic data when incorporating functional endpoints into ... to toxicology studies has evolved from short ECG ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and ... the addition of the "Biometrics Market in ... http://photos.prnewswire.com/prnh/20130307/600769 ... projects such as rural banking and upgradation of ... trends witnessed in the market. Besides the aforementioned ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... -- A two-year study of college students at ... learn better and develop higher-level skills by participating ... teaching methods. Elsa Snchez and Richard Craig, ... surveyed students enrolled from 2003-2005 in their Plant ...
... -- We love it fresh, canned and frozen. It,s grown ... by the American Society of Horticultural Science, adds up to ... In other words, sweet corn is big business. Fresh ... July, with only ten percent of the annual volume marketed ...
... Two common dietary molecules found in legumes and ... of radiation, researchers from the University of Maryland ... human skin cells and a skin cancer-prone mouse ... damaging radiation found in sunlight, the team reported ...
Cached Biology News:Teamwork improves learning and career success 2How sweet is it? 2Antioxidants could provide all-purpose radiation protection 2Antioxidants could provide all-purpose radiation protection 3
Ideal for chemical processing that requires downward flow of exhaust fumes. Powderful 1200 CFM blower draws fumes into sub-surface bonded charcoal filter for safe removal of organic vapors (final HEP...
... Shimadzus preparative LC/MS, using mass numbers as ... it ideal for performing investigation and research ... for both analytical and preparative operation. Switching ... in the software. This support provides a ...
... Label IT siRNA Tracker Intracellular Localization Kit ... label and deliver siRNA, of your design, ... in vitro tracking experiments. Subcellular localization and ... be monitored following introduction of the labeled ...
Selective media for Salmonella...
Biology Products: